{"id":"rebamipide-and-esomeprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1697771","moleculeType":"Small molecule","molecularWeight":"370.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rebamipide is a mucoprotective agent that enhances gastric mucus secretion, increases mucosal blood flow, and promotes healing of gastric lesions. Esomeprazole is a proton pump inhibitor that suppresses gastric acid production by blocking H+/K+-ATPase in parietal cells. Together, they provide dual protection and healing of the gastric mucosa in acid-peptic diseases.","oneSentence":"This combination product uses rebamipide to protect and promote gastric mucosa healing while esomeprazole reduces gastric acid secretion to treat acid-related disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:03.770Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric ulcer"},{"name":"Duodenal ulcer"},{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Gastritis"}]},"trialDetails":[{"nctId":"NCT02134405","phase":"PHASE4","title":"Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2014-08","conditions":"Dyspepsia","enrollment":200},{"nctId":"NCT00641004","phase":"PHASE4","title":"Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical, Inc., Philippines","startDate":"2008-04","conditions":"NSAID Induced Gastropathy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rebamipide and Esomeprazole","genericName":"Rebamipide and Esomeprazole","companyName":"Otsuka Pharmaceutical, Inc., Philippines","companyId":"otsuka-pharmaceutical-inc-philippines","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination product uses rebamipide to protect and promote gastric mucosa healing while esomeprazole reduces gastric acid secretion to treat acid-related disorders. Used for Gastric ulcer, Duodenal ulcer, Gastroesophageal reflux disease (GERD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}